Doxorubicin

Doxorubicin is an intravenous chemotherapy drug in the anthracycline family that damages cancer cell DNA and blocks an enzyme (topoisomerase II) the cells need to divide. It has historically been one of the few drugs with measurable activity against mesothelioma and some sarcomas, though it is no longer first-line for pleural mesothelioma.

Origin

Doxorubicin was isolated in the 1960s from the soil bacterium Streptomyces peucetius var. caesius by researchers at Farmitalia in Italy. Its bright red color led to the brand name Adriamycin, after the Adriatic Sea near where the organism was found.

Significance in Asbestos Context

For decades, doxorubicin was a backbone of mesothelioma chemotherapy, and it is still used, often in second-line treatment, in peritoneal mesothelioma regimens, or in combination protocols when platinum-pemetrexed stops working. Patients should know that doxorubicin has a lifetime cumulative dose limit because of its risk of heart damage (cardiotoxicity), so oncologists track every dose received; this matters if you change cancer centers or pursue clinical trials later. Records of total doxorubicin dose, baseline and follow-up echocardiograms or MUGA scans, and any documented heart-function changes also become part of the medical record that supports damages in a legal claim, because cardiotoxicity is a real and compensable consequence of treatment.

Example Sentence

After her peritoneal mesothelioma progressed on pemetrexed and cisplatin, her oncologist added doxorubicin and ordered an echocardiogram first to confirm her heart could tolerate it.

Related Terms

Chemotherapy, Mesothelioma, Pemetrexed, Cisplatin, Cardiotoxicity, Second-Line Therapy

Notes

• Ask your oncologist for your cumulative doxorubicin dose (in mg/m²) at every visit and keep a written record. The lifetime cap is typically around 450–550 mg/m² to limit heart risk.
• Request a baseline echocardiogram or MUGA scan before starting, and repeat heart imaging during and after treatment; report any new shortness of breath, swelling, or irregular heartbeat immediately.
• Expect red-tinted urine for 1–2 days after each infusion (harmless), along with possible hair loss, mouth sores, low blood counts, and nausea. Ask about anti-nausea premedication and infection precautions.
• Preserve all infusion records, dose summaries, and cardiac test results; these document both your treatment burden and any lasting cardiac injury for your medical and legal files.